Biomics Biopharma (ASX:BBM) EBITDA Margin %: 0.00% (As of . 20)


What is Biomics Biopharma EBITDA Margin %?

Biomics Biopharma ASX:BBM EBITDA Margin % is 0.00% as of . 20.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biomics Biopharma's EBITDA for the six months ended in . 20 was A$0.00 Mil. Biomics Biopharma's Revenue for the six months ended in . 20 was A$0.00 Mil. Therefore, Biomics Biopharma's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Biomics Biopharma  (ASX:BBM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Biomics Biopharma EBITDA Margin % Related Terms

Biomics Biopharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma EBITDA Margin % Chart

Biomics Biopharma Annual Data
Trend
EBITDA Margin %

Biomics Biopharma Semi-Annual Data
EBITDA Margin %

Biomics Biopharma EBITDA Margin % Competitor Comparison

For the Biotechnology subindustry, Biomics Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomics Biopharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's EBITDA Margin % falls into.


Biomics Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Biomics Biopharma's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Biomics Biopharma's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Biomics Biopharma (ASX:BBM) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's EBITDA Margin % too high?
Biomics Biopharma's current EBITDA Margin % is 0.00%.
How does Biomics Biopharma's EBITDA Margin % compare to competitors?
Biomics Biopharma's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biomics Biopharma and its competitors. Biomics Biopharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.